NewTimeSpace News, as of 10:42 on March 16, 2026, Innovative Medicine ETF (E Fund) (516080) rose 0.48%, with the latest price at 0.63 yuan. Looking at a longer time frame, as of March 13, 2026, Innovative Medicine ETF (E Fund) has cumulatively gained 11.74% over the past year, ranking 1st among 7 comparable funds in terms of gains. (The stocks listed above are index constituents only and do not represent specific recommendations.)

In terms of liquidity, Innovative Medicine ETF (E Fund) recorded a turnover rate of 1.08% intraday, with trading volume reaching 13.1272 million yuan. Looking at a longer time frame, as of March 13, the average daily trading volume over the past month was 22.3408 million yuan, ranking among the top 3 comparable funds.

In terms of scale, Innovative Medicine ETF (E Fund) has grown by 25.1688 million yuan over the past week, achieving significant growth and ranking 3rd among 7 comparable funds in terms of new scale additions. (Data Source: Wind)

In terms of shares, Innovative Medicine ETF (E Fund) has reached 1.912 billion shares most recently, hitting a new high for the past year and ranking 3rd among 7 comparable funds. (Data Source: Wind)

Regarding capital inflows, Innovative Medicine ETF (E Fund) has recorded consecutive net capital inflows for the past 6 days, with a maximum single-day net inflow of 9.3224 million yuan, totaling 28.978 million yuan in "capital attraction," with an average daily net inflow of 4.8297 million yuan. (Data Source: Wind)

Data shows that leveraged funds continue to build positions. Innovative Medicine ETF (E Fund) recorded a latest margin purchase amount of 2.0434 million yuan, with the latest financing balance reaching 22.3561 million yuan. (Data Source: Wind)

As of March 13, Innovative Medicine ETF (E Fund) has risen 14.09% in net asset value over the past 1 year, ranking first among comparable funds. In terms of return capability, as of March 13, 2026, since its inception, Innovative Medicine ETF (E Fund) has achieved a maximum monthly return of 22.96%, a longest consecutive rising streak of 5 months, a maximum consecutive gain of 33.43%, and an average return of 5.75% during rising months. As of March 13, 2026, the annualized excess return over the benchmark since inception is 3.14%.

In terms of drawdown, as of March 13, 2026, the relative benchmark drawdown of Innovative Medicine ETF (E Fund) year-to-date is 0.03%, representing the smallest drawdown among comparable funds.

In terms of fees, Innovative Medicine ETF (E Fund) has a management fee of 0.15% and a custody fee of 0.05%, representing the lowest fee structure among comparable funds.

Regarding tracking accuracy, as of March 13, 2026, the 1-month tracking error of Innovative Medicine ETF (E Fund) is 0.009%, representing relatively high tracking accuracy among comparable funds.

From a valuation perspective, the CSI Innovative Medicine Industry Index tracked by Innovative Medicine ETF (E Fund) has a latest price-to-earnings ratio (PE-TTM) of only 47.25x, at the 12.17th percentile over the past year, meaning the valuation is lower than 87.83% of the time over the past year, placing it at a historical low.

Innovative Medicine ETF (E Fund) closely tracks the CSI Innovative Medicine Industry Index. The CSI Innovative Medicine Industry Index selects up to 50 most representative securities from listed companies whose main business involves innovative drug research and development as index samples, aiming to reflect the overall performance of securities of listed companies in the innovative medicine industry.

Dongguan Securities stated that recently the pharmaceutical and biotechnology sector has continued to correct, with most sub-sectors showing sustained weakness, while some medical consumables sub-sectors at low levels have shown some performance. As the innovative drug sector continues to correct, the current investment risk-reward ratio is gradually improving, and the firm subsequently recommends investment opportunities in the innovative drug industry chain.

Sinolink Securities believes that the turning point for innovative drug companies' profitability has arrived, with dense clinical data catalysts throughout the year, combined with smooth progress in overseas clinical trials for already BD-licensed pipelines. The firm is optimistic about investment opportunities in the innovative drug sector.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.